Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia

American Journal of Respiratory Cell and Molecular Biology

Volumn 40, Issue 4, 2009, Pages 474-481

  Reppe, Katrin ^a   Tschernig, Thomas ^b   Luhrmann, Anke ^b   Van Laak, Vincent ^a   Grote, Karsten ^c   Zemlin, Maren V ^a   Gutbier, Birgitt ^a   Miiller, Holger C ^a   Kursar, Mischo ^d   Schiitte, Hartwig ^a   Rosseau, Simone ^a   Pabst, Reinhard ^b   Suttorp, Norbert ^a   Witzenrath, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b institute of Functional and Applied Anatomy ^*

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Immunostimulation; MALP 2; Pneumococcal pneumonia; TLR 2

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RANTES; TOLL LIKE RECEPTOR 2; CYTOKINE; LIPOPEPTIDE; MACROPHAGE STIMULATORY LIPOPEPTIDE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BODY WEIGHT; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOTHERMIA; IMMUNOSTIMULATION; INFLAMMATORY INFILTRATE; LEUKOCYTE COUNT; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIA; SURVIVAL; ANIMAL; CELL MOTION; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNIZATION; IMMUNOLOGY; LEUKOCYTE; LUNG; METABOLISM; MICROBIOLOGY; PATHOLOGY; SECRETION;

BACTERIA (MICROORGANISMS); MURINAE; MUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTEREMIA; CELL MOVEMENT; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNIZATION; LEUKOCYTES; LIPOPEPTIDES; LUNG; MICE; PNEUMONIA, PNEUMOCOCCAL; RNA, MESSENGER; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 2;

EID: 63349095712     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0071OC     Document Type: Article

References (50)

1. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001.
2. Kadioglu A, Andrew PW. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol 2004;25:143-149.
3. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J 2007;30:1193-1207.
4. File TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004;117:39-50.
5. Hament JM, Kimpen JLL, Fleer A, Wolfs TFW. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999;26:189-195.
6. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 2007;280:21-27.
7. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449:819-826.
8. Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, Kirschning CJ. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol 2003;170:438-444.
9. Letiembre M, Echchannaoui H, Bachmann P, Ferracin F, Nieto C, Espinosa M, Landmann R. Toll-like receptor 2 deficiency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes. Infect Immun 2005;73:8397-8401.
10. Schmeck B, Huber S, Moog K, Zahlten J, Hocke AC, Opitz B, Hammerschmidt S, Mitchell TJ, Kracht M, Rosseau S, et al. Pneumococci induced TLR- and Racl-dependent NF-kappa B-recruitment to the IL-8 promoter in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L730-L737.
11. Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008;177:1322-1330.
12. Karaolis DK, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, Bhan U, Liang H, Standiford TJ. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 2007;75:4942-4950.
13. Jean D, Rezaiguia-Delclaux S, Delacourt C, Leclercq R, Lafuma C, Brun-Buisson C, Harf A, Delclaux C. Protective effect of endotoxin instillation on subsequent bacteria-induced acute lung injury in rats. Am J Respir Crit Care Med 1998;158:1702-1708.
14. Empey KM, Hollifield M, Garvy BA. Exogenous heat-killed escherichia coli improves alveolar macrophage activity and reduces Pneumocystis carinii lung burden in infant mice. Infect Immun 2007;75:3382- 3393.
15. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J. Immunol 2004;173:5148-5155.
16. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-1958.
17. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S. Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2-and MyD88-dependent signaling pathway. J Immunol 2000;164:554-557.
18. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S. Discrimination of bacterial lipoproteins by Tolllike receptor 6. Int Immunol 2001;13:933-940.
19. Kaufmann A, Muhlradt PF, Gemsa D, Sprenger H. Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun 1999;67: 6303-6308.
20. Deiters U, Muhlradt PF. Mycoplasmal lipopeptide MALP-2 induces the chemoattractant proteins macrophage inflammatory protein 1 alpha (MIP-1 alpha), monocyte chemoattractant protein 1, and MIP-2 and promotes leukocyte infiltration in mice. Infect Immun 1999;67:3390- 3398.
21. Luhrmann A, Deiters U, Skokowa J, Hanke M, Gessner JE, Muhlradt PF, Pabst R, Tschernig T. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect Immun 2002;70:3785-3792.
22. Feterowski C, Novotny A, Kaiser-Moore S, Muhlradt PF, Rossmann- Bloeck T, Rump M, Holzmann B, Weighardt H. Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation. Int Immunol 2005;17: 1035-1046.
23. Costa DL, Lehmann JR, Harold WM, Drew RT. Transoral tracheal intubation of rodents using a fiberoptic laryngoscope. Lab Anim Sci 1986;36:256-261.
24. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
25. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, Berger K, Mitchell TJ, de los Toyos JR, Rosseau S, Suttorp N, et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006;34:1947-1954.
26. Schmeck B, Zahlten J, Moog K, van Laak V, Huber S, Hocke AC, Opitz B, Hoffmann E, Kracht M, Zerrahn J, et al. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem 2004;279:53241-53247.
27. Morton DB. Adverse effects in animals and their relevance to refining scientific procedures. Altern Lab Anim 1990;18:29-39.
28. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005;105:3569-3576.
29. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos- Cuentas A, Pollack H. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44:1549-1554.
30. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiftman M, Afdhal NH, Jacobson IM, Muir A, Al Adhami M, Morris ML, et al. Phase IB, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46:1341- 1349.
31. Deiters U, Barsig J, Tawil B, Muhlradt PF. The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice. Exp Dermatol 2004;13:731-739.
32. Tschernig T, Luhrmann A, Pabst R. Recruitment of lymphocytes and dendritic cells from the blood to the bronchoalveolar space and the draining lymph nodes after a single intrabronchial application of the lipopeptide MALP-2. Pathobiology 2002;70:260-265.
33. Rharbaoui F, Westendorf A, Link C, Felk S, Buer J, Gunzer M, Guzman CA. The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosaassociated lymphoid tissues. Infect Immun 2004;72:6978-6986.
34. Hocke AC, Lampe MP, Witzenrath M, Mollenkopf H, Zerrahn J, Schmeck B, Kessler U, Krull M, Hammerschmidt S, Hippenstiel S, et al. Cell-specific interleukin-15 and interleukin-15 receptor subunit expression and regulation in pneumococcal pneumonia-comparison to chlamydial lung infection. Cytokine 2007;38:61-73.
35. Morr M, Takeuchi O, Akira S, Simon MM, Muhlradt PF. Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol 2002;32:3337-3347.
36. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
37. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7: 353-364.
38. Luhrmann A, Grote K, Stephan M, Tschernig T, Pabst R. Local pulmonary immune stimulation by the Toll-like receptor 2 and 6 ligand MALP-2 in rats is age dependent. Immunol Lett 2007;108:167-173.
39. Gao H, Leaver SK, Burke-Gaffney A, Finney SJ. Severe sepsis and Tolllike receptors. Semin Immunopathol 2007;30:29-40.
40. Meng G, Rutz M, Schiemann M, Metzger J, Grabiec A, Schwandner R, Luppa PB, Ebel F, Busch DH, Bauer S, et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 2004;113:1473-1481.
41. Koedel U, Bernatowicz A, Frei K, Fontana A, Pfister HW. Systemically (but not intrathecally) administered IL-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis. J Immunol 1996;157:5185-5191.
42. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
43. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, Goldman M, Jansen HM, Lutter R, van der Poll T. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004;172:7603-7609.
44. Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W III, Sampson JS, Stiles JK, et al. CCL5 modulates pneumococcal immunity and carriage. J Immunol 2006; 176:2346-2356.
45. Ben David I, Price SE, Bortz DM, Greineder CF, Cohen SE, Bauer AL, Jackson TL, Younger JG. Dynamics of intrapulmonary bacterial growth in a murine model of repeated microaspiration. Am J Respir Cell Mol Biol 2005;33:476-482.
46. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response.J Immunol 2000; 165:4537-4543.
47. Cluff CW, Baldridge JR, Stover AG, Evans JT, Johnson DA, Lacy MJ, Clawson VG, Yorgensen VM, Johnson CL, Livesay MT, et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005;73:3044-3052.
48. Pabst R, Tschernig T. Perivascular capillaries in the lung: An important but neglected vascular bed in immune reactions? J Allergy Clin Immunol 2002;110:209-214.
49. Garcia X, Stein F. Nitric oxide. Semin Pediatr Infect Dis 2006;17:55-57.
50. Wilde I, Lotz S, Engelmann D, Starke A, van Zandbergen G, Solbach W, Laskay T. Direct stimulatory effects of the TLR2/6 ligand bacterial lipopeptide MALP-2 on neutrophil granulocytes. Med Microbiol Immunol (Berl) 2007;196:61-71.